EPAS1 and non-small cell lung carcinoma: Studies have shown that EPAS1 promotes peritoneal carcinogenesis in NSCLC patients by enhancing MMT (mesothelial-mesenchymal transition), therefore, it is a potential prognostic marker or therapeutic target for NSCLC 17.